Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ETBusiness Wire • 11/28/23
Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 MillionBusiness Wire • 11/02/23
Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. ESTBusiness Wire • 10/30/23
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development OfficerPRNewsWire • 09/11/23
Seres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceBusiness Wire • 09/07/23
Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdatesBusiness Wire • 08/08/23
Seres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023Business Wire • 08/01/23
Seres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth ConferenceBusiness Wire • 08/01/23
Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule DrugsPRNewsWire • 06/21/23
Seres Therapeutics and Nestlé Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023Business Wire • 06/17/23
Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile InfectionBusiness Wire • 06/05/23
Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST™Business Wire • 05/30/23